AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1964153
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy using three different drug-combinations (A: 1500 mg/m2 cyclophosphamide, 100 mg/m2 lomustine, 15 mg/m2 methotrexate; B: 1000 mg/m2 cyclophosphamide, 40 mg/m2 doxorubicin, 1 mg/m2 vincristine; C: 5 x 1.6 g/m2 ifosfamide plus mesna, 5 x 120 mg/m2 etopside)
Trial: 1964153
Drug: Surgery followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surgery followed by chemotherapy and radiotherapy
Trial: 418984
Drug: Monistat Cream
RxNorm normalized name: Monistat
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Monistat Cream for 7 days
Trial: 418984
Drug: Monistat Cream
RxNorm normalized name: Monistat
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Monistat Cream for 14 days
Trial: 30520013
Drug: 12 infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 infusions of rituximab (375 mg/m2) in combination with CHOEP chemotherapy
Trial: 30520013
Drug: 6 infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 infusions of rituximab (375 mg/m2) in combination with CHOEP chemotherapy (control group)
Trial: 22209640
Drug: Stimulant medication
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant medication (individualized dose of psychostimulants such as methylphenidate or dextroamphetamine/amphetamine combination)
Trial: 15314858
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin administration in doses exceeding routine ones
Trial: 11889659
Drug: Tailored self-care
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tailored self-care treatment program
Trial: 11889659
Drug: Usual TMD
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual TMD treatment
Trial: 9797623
Drug: Morphine (n=62)
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine (n=62)
Trial: 9797623
Drug: Non-morphine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-morphine treatment (n=33)
Trial: 2378776
Drug: Propofol (1.34
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.34 mg/kg of LTM for ED50, 2.56 mg/kg of LTM for ED95)
Trial: 334609
Drug: Butacote, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butacote, 200 mg b.d. for four weeks
Trial: 334609
Drug: Naproxen, 250
RxNorm normalized name: Naproxen, 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen, 250 mg b.d. for four weeks
Trial: 19185773
Drug: GoChi (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GoChi (120 mL/d)
Trial: 10197889
Drug: Adjunctive megavitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive megavitamin and dietary treatment
Trial: 10197889
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving 25 mg vitamin C and allergenic substances
Trial: 8527549
Drug: Rifabutin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifabutin (600 mg/d) in combination with ethambutol, streptomycin, and clarithromycin (500 mg b.i.d.)
Trial: 8527549
Drug: Rifabutin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifabutin (600 mg/d) in combination with ethambutol, streptomycin, and azithromycin (600 mg/d)
Trial: 7948562
Drug: Rifabutin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifabutin (600 mg/d)
Trial: 2273082
Drug: Methyldopa (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (250 mg tid) for 14 days
Trial: 7378251
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Phyllocontin Continus tablets and salbutamol)
Trial: 30677187
Drug: Usual basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual basal insulin dose
Trial: 30677187
Drug: Reduced (75%)
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced (75%) basal insulin dose
Trial: 23449126
Drug: Topical enzymatically
RxNorm normalized name: hydrolyzed sericin (enzymatic; 2500 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical enzymatically generated hydrogen peroxide (using glucose oxidase and glucose)
Trial: 19811710
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% diltiazem hydrochloride, applied perianally twice daily for 8 weeks
Trial: 19811710
Drug: 0.2% glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% glyceryl trinitrate (GTN), applied perianally twice daily for 8 weeks
Trial: 15079108
Drug: Hypertonic colloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic colloid solution (250 ml of 7.2% NaCl/6% Hydroxyethylstarch)
Trial: 15079108
Drug: Usual Ringer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Ringer solution (control group)
Trial: 11679441
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of nitroglycerin (GTN) at 1 microg.kg(‐1).min(‐1) for 4 hours
Trial: 7524141
Drug: alfuzosin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfuzosin 2.5 mg TID
Trial: 30113638
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment 1 mg/m2/d (≈0.035 mg/kg/d)
Trial: 23963307
Drug: Drospirenone 0.25
RxNorm normalized name: drospirenone 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone 0.25 mg/17β‐estradiol 0.5 mg
Trial: 23963307
Drug: Drospirenone 0.5
RxNorm normalized name: drospirenone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone 0.5 mg/17β‐estradiol 0.5 mg
Trial: 23963307
Drug: 17β‐estradiol 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17β‐estradiol 0.3 mg
Trial: 18952561
Drug: 4 courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 courses of anthracycline-based chemotherapy followed by 4 courses of docetaxel or paclitaxel in combination with trastuzumab, followed by 14 additional courses of trastuzumab (total of 18 doses)
Trial: 18952561
Drug: 3 courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 courses of 3-weekly docetaxel in combination with weekly trastuzumab (total of 9 doses) followed by 3 courses of 5-fluorouracil/epirubicin/cyclophosphamide
Trial: 10861325
Drug: Bacille Calmette‐Guérin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacille Calmette‐Guérin vaccine
Trial: 8971495
Drug: Phosphocreatine (PCr)
RxNorm normalized name: phosphocysteamine
DrugBank: Phosphocreatine (DB13191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphocreatine (PCr) administration
Trial: 18675744
Drug: Placebo (isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (isotonic NaCl solution)
Trial: 30352784
Drug: Selinexor (60,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor (60, 80, or 100 mg orally) plus bortezomib (1.3 mg/m2 subcutaneously) and dexamethasone (20 mg orally) once or twice weekly in 21- or 35-day cycles.
Trial: 30352784
Drug: Selinexor (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor (100 mg once weekly), bortezomib (1.3 mg/m2 once weekly for 4 weeks), and dexamethasone (40 mg once weekly) per 35-day cycle (recommended phase 2 dose).
Trial: 22919238
Drug: Rectal indomethacin
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal indomethacin administered immediately after ERCP
Trial: 12214938
Drug: Artemether (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether (1.6 mg/kg body wt., repeated after 12 hrs and then daily for four days)
Trial: 12214938
Drug: Quinine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (10 mg/kg body wt in 10 ml/kg body wt of 5% dextrose in 0.9% saline intravenously, repeated every 8 hrs and changed to oral administration when the child was able to drink to finish seven days)
Trial: 7740949
Drug: Oral cefadroxil
RxNorm normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cefadroxil
Trial: 2633082
Drug: CP-enriched cardioplegia
RxNorm normalized name: methylcellulose (1500 CPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-enriched cardioplegia at a concentration of 10 mmol/l
Trial: 26601565
Drug: Imiquimod cream
RxNorm normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod cream
Trial: 25581584
Drug: Fluorouracil cream
RxNorm normalized name: Fluorouracil Cream
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil cream
Trial: 17941858
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (up to 105 mg/day)
Trial: 17941858
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (over 90 mg/day)
Trial: 15001200
Drug: Olmesartan medoxomil/HCTZ
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil/HCTZ 20/12.5 mg
Trial: 15001200
Drug: Olmesartan medoxomil/HCTZ
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil/HCTZ 40/25 mg
Trial: 9787943
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) at a dose of 2 g/d
Trial: 12589521
Drug: Buspirone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (30 mg orally)
Trial: 2475681
Drug: Sustained-release verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release verapamil (240-mg tablets), given once or twice daily
Trial: 367715
Drug: Syndol (analgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syndol (analgesic combination)
Trial: 28668970
Drug: Intermittent pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent pneumatic compression (IPC) for 2 weeks, 6 hours daily bilateral calf IPC applied under an orthosis on the injured side.
Trial: 28668970
Drug: Treatment-as-usual (plaster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (plaster cast without IPC) for 2 weeks.
Trial: 30952794
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium 220 mg twice daily
Trial: 29066877
Drug: Intranasal salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal salmon calcitonin (200 IU/day)
Trial: 10386278
Drug: Succinylcholine 1
RxNorm normalized name: Succinylcholine 124 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1 to 1.5 mg/kg
Trial: 1763654
Drug: Clonidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (300 micrograms daily)
Trial: 1763654
Drug: Bromocryptine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocryptine (5 mg daily)
Trial: 26607249
Drug: Sodium nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium nitrite (80 or 160 mg/day, capsules, TheraVasc)
Trial: 21457066
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin glulisine (GLU)
Trial: 21457066
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart (ASP)
Trial: 22240636
Drug: Pomegranate seed
RxNorm normalized name: pomegranate seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate seed oil (PGS) 30 mg, 127 μg of steroidal phytoestrogens per dose, taken twice daily for 12 weeks
Trial: 18575579
Drug: D3 receptor‐preferring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D3 receptor‐preferring agonist pramipexole
Trial: 10454450
Drug: EPA (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA (4 g/d)
Trial: 2185155
Drug: Clavulanate‐potentiated amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clavulanate‐potentiated amoxicillin (Augmentin)
Trial: 26558386
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation combined with constraint-induced movement therapy
Trial: 26558386
Drug: Sham stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham stimulation with constraint-induced movement therapy
Trial: 19432500
Drug: TZP-101 single
RxNorm normalized name: TZP-102
DrugBank: TZP-102 (DB16129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TZP-101 single doses (160-600 microg/kg)
Trial: 19432500
Drug: TZP-101 multiple
RxNorm normalized name: TZP-102
DrugBank: TZP-102 (DB16129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TZP-101 multiple doses (80-600 microg/kg/day)
Trial: 16143120
Drug: Certolizumab 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Certolizumab 100 mg
Trial: 16143120
Drug: Certolizumab 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Certolizumab 400 mg (in patients with baseline C-reactive protein levels of 10 mg/L or greater)
Trial: 16143120
Drug: Placebo (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (in patients with baseline C-reactive protein levels of 10 mg/L or greater)
Trial: 11865831
Drug: Pentoxifylline (PXF)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PXF) 1600 mg daily
Trial: 10206296
Drug: 5‐Fluorouracil (5FU)‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐Fluorouracil (5FU)‐based chemotherapy
Trial: 2159990
Drug: Desciclovir, 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desciclovir, 250 mg three times a day for 14 days
Trial: 18212314
Drug: Chlorthalidone (diuretic)
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (diuretic)
Trial: 18212314
Drug: Doxazosin (alpha-blocker)
RxNorm normalized name: ALPHA BLOCKERS/RELATED
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxazosin (alpha-blocker)
Trial: 27084978
Drug: USL255 (topiramate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USL255 (topiramate extended-release capsules) up to 400 mg/day
Trial: 23909985
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg/day plus pioglitazone 15 mg
Trial: 23909985
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg/day plus pioglitazone 30 mg
Trial: 23909985
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg/day plus pioglitazone 45 mg
Trial: 23909985
Drug: All combination-treated
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All combination-treated groups
Trial: 22419733
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment during euglycemic-hyperinsulinemic clamp
Trial: 22419733
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment during hyperglycemic-hyperinsulinemic clamp
Trial: 22419733
Drug: High glucose
RxNorm normalized name: ONE TOUCH HIGH GLUCOSE CONTROL SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High glucose and insulin treatment in monocytes
Trial: 21287477
Drug: Lidocaine 5%
RxNorm normalized name: LIDOCAINE 5% OINT
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 5% (75 mg) and 10 micrograms sufentanil
Trial: 21287477
Drug: Lidocaine 5%
RxNorm normalized name: LIDOCAINE 5% OINT
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 5% (75 mg) and 5 micrograms sufentanil
Trial: 21287477
Drug: Lidocaine 5%
RxNorm normalized name: LIDOCAINE 5% OINT
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 5% (75 mg) and 2 ml of normal saline (control group)
Trial: 18385198
Drug: Temsirolimus i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus i.v. 25 mg weekly
Trial: 18385198
Drug: Temsirolimus i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus i.v. 15 mg weekly plus interferon s.c. 6 MU thrice weekly
Trial: 18385198
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa (IFN) s.c. up to 18 MU thrice weekly
Trial: 11813224
Drug: Anti-lymphocyte antibody
RxNorm normalized name: lymphocyte immune globulin, anti-thymocyte globulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-lymphocyte antibody induction therapy
Trial: 8566881
Drug: Levosulpiride (LS)
RxNorm normalized name: bisoprolol fumarate Oral Tablet [Emcor LS]
DrugBank: Levosulpiride (DB16021)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosulpiride (LS) regimen (higher dose on day 8)
Trial: 8566881
Drug: Metoclopramide (MTC)
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide (MTC) regimen (higher dose on day 8)
Trial: 2147736
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg norgestrel + (Cyclo‐Progynova)
Trial: 2147736
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg cyproterone acetate (SH D 461 A)
Trial: 31016671
Drug: Gentamicin 5
RxNorm normalized name: gentamicin 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 5 mg/kg based on lean body weight in morbidly obese individuals
Trial: 31016671
Drug: Gentamicin 5
RxNorm normalized name: gentamicin 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 5 mg/kg based on total body weight in non-obese individuals
Trial: 22761551
Drug: Constraint induced
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint induced movement therapy (CIMT)
Trial: 19562243
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment of osteoporosis (control group)
Trial: 11429352
Drug: Inhaled anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled anesthesia with isoflurane
Trial: 9605995
Drug: Bereavement support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bereavement support group intervention (10-week, once weekly, 90-min/session)
Trial: 7993207
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment with a 1 microgram/h ganciclovir implant
Trial: 7993207
Drug: Ganciclovir implant
RxNorm normalized name: ganciclovir Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir implant
Trial: 2691815
Drug: 15 g.100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g.100 ml‐1 glucose (G)
Trial: 2691815
Drug: 15 g.100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g.100 ml‐1 maltodextrin plus 3 g.100 ml‐1 fructose (MD)
Trial: 2691815
Drug: 7 g.100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g.100 ml‐1 sucrose (I)
Trial: 26278231
Drug: Venlafaxine extended-release
RxNorm normalized name: Desvenlafaxine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine extended-release (#300 mg per day) for 12-14 weeks
Trial: 21654268
Drug: Febuxostat 60
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat 60 mg/d
Trial: 19781407
Drug: Intensive statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive statin therapy (atorvastatin, 20 or 40 mg/d, or equivalent dose of other statins)
Trial: 19781407
Drug: Standard statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard statin therapy (atorvastatin, 10 mg/d, or equivalent dose of other statins)
Trial: 15502598
Drug: Paroxetine (10‐50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (10‐50 mg/day)
Trial: 11775645
Drug: Essaven gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essaven gel (EG) - single acute application
Trial: 7919329
Drug: rhIL‐3 (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL‐3 (2.5 or 5.0 micrograms/kg/day) administered by subcutaneous injection for either 5 or 10 days starting 4 hours after the marrow infusion followed by rhGM‐CSF (250 micrograms/m2/d as a 2‐hour intravenous infusion) until ANC > or = 1,500/microL for 3 consecutive days or until day 27 posttransplant.
Trial: 7919329
Drug: rhGM‐CSF (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGM‐CSF (250 micrograms/m2/d as a 2‐hour intravenous infusion) administered after rhIL‐3.
Trial: 30054842
Drug: CEGP-003 spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEGP-003 spray
Trial: 20715595
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day of algal DHA
Trial: 16546105
Drug: MMC, 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMC, 0.2 mg/ml applied for three minutes (Group 1)